文献速递淋巴瘤

接受治疗的浆母细胞淋巴瘤患者生存分析:一项基于人群的研究

Survival analysis in treated plasmablastic lymphoma patients: a population-based study.
PubMed 文献 · Am J Hematol · 2020-08-26

基于SEER 18登记数据库分析2010至2016年接受化疗的浆母细胞淋巴瘤患者248例,3年和5年总生存率分别为54%和52.8%,口腔原发部位与更好的总生存和淋巴瘤特异性生存相关,HIV状态未影响生存。

要点

  • 接受化疗的浆母细胞淋巴瘤患者3年和5年总生存率分别为54%和52.8%。
  • 口腔原发部位与更好的总生存(HR 0.43)和淋巴瘤特异性生存(SHR 0.36)相关。
  • 年龄≥60岁与更短的淋巴瘤特异性生存相关(SHR 1.73)。

核心结论

  • 研究识别了与浆母细胞淋巴瘤生存相关的临床特征,并显示接受治疗的患者可能获得长期生存。

研究设计与样本

  • 基于SEER 18登记数据库(2019年4月发布,基于2018年11月提交数据)的人群研究,纳入2010至2016年诊断且接受化疗的浆母细胞淋巴瘤患者248例。

主要发现

  • 多数患者为男性(81.9%)且年龄小于60岁(71.0%)。
  • 口腔和胃肠道是最常见的原发结外部位(分别为23%和19.4%)。
  • 口腔原发部位与B症状和晚期Ann-Arbor分期的存在呈负相关。
  • 接受治疗患者3年和5年总生存率分别为54%(95% CI:46.5%-60.8%)和52.8%(95% CI:45.2%-59.8%)。
  • 2年生存者和3年生存者的3年条件生存率分别为90.3%和97.8%,与按年龄、性别和日历年匹配的一般人群生存率重叠。

关键数值与推荐

  • 多变量分析中,口腔原发部位与更好的总生存相关(HR 0.43;95% CI:0.21-0.88,P = .021)。
  • 口腔原发部位与更好的淋巴瘤特异性生存相关(SHR 0.36;95% CI:0.15-0.86,P = .022)。
  • 年龄≥60岁与更短的淋巴瘤特异性生存相关(SHR 1.73;95% CI:1.02-2.96,P = .043)。
  • 7个登记处提供HIV状态(n = 93),其中52.7%的病例检出HIV感染;HIV状态在未调整和调整分析中均未影响生存结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herein we analyzed survival outcomes in chemotherapy-treated patients with plasmablastic lymphoma (PBL) diagnosed between 2010 to 2016 (n = 248). Data was acquired from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database (April 2019 release based on November 2018 submission). The majority of patients were male (81.9%) and younger than 60 years (71.0%). Oral and gastrointestinal (GI) sites were the most frequent primary extranodal locations (23% and 19.4%, respectively). Oral primary location was inversely associated with presence of B symptoms and advanced Ann-Arbor stage. The 3-year and 5-year overall survival (OS) rates of treated PBL patients were 54% (95% CI: 46.5%-60.8%) and 52.8% (95% CI: 45.2%-59.8%). Three-year conditional survival for 2-year and 3-year survivors were 90.3% and 97.8%, overlapping the survival of a general population matched by age, sex and calendar year. In a multivariable analysis, oral primary location was associated with not only better OS (HR 0.43; 95% CI: 0.21-0.88, P = .021) but also better lymphoma-specific survival (LSS) (SHR 0.36; 95% CI: 0.15-0.86, P = .022); age ≥60 years was associated with shorter LSS (SHR 1.73; 95% CI: 1.02-2.96, P = .043). Seven registries granted access to HIV status (n = 93) where HIV infection was detected in 52.7% of cases. The HIV status did not affect survival outcomes in unadjusted and adjusted analyses. We identified clinical characteristics associated with survival and showed that treated PBL patients may achieve long-term survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Florindez JA, Alderuccio JP, Reis IM, et al. Survival analysis in treated plasmablastic lymphoma patients: a population-based study. Am J Hematol. 2020. PMID: 32777103. doi:10.1002/ajh.25955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。